Overview

Olema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers. Olema’s lead product candidate, OP-1250, a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), is currently being studied in a Phase 1/2 clinical trial for the treatment of recurrent, metastatic or locally advanced ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema is headquartered in San Francisco.

 

Latest Presentation

Stock Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News Releases

28 Jul '2021
SAN FRANCISCO, July 28, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced that Sean P.

Events & Presentations

SEC Filings

Filing date Description Form

Annual report which provides a comprehensive overview of the company for the past year

10-K

Quarterly report which provides a continuing view of a company's financial position

10-Q

Quarterly report which provides a continuing view of a company's financial position

10-Q